These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12464779)

  • 21. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
    Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
    J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK; Jauw YW; de Bree R; Roos JC; Castelijns JA; Leemans CR; van Dongen GA; Boellaard R
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient dosimetry of intravenously administered 99mTc-annexin V.
    Kemerink GJ; Liem IH; Hofstra L; Boersma HH; Buijs WC; Reutelingsperger CP; Heidendal GA
    J Nucl Med; 2001 Feb; 42(2):382-7. PubMed ID: 11216539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
    Crombet T; Torres L; Neninger E; Catalá M; Solano ME; Perera A; Torres O; Iznaga N; Torres F; Pérez R; Lage A
    J Immunother; 2003; 26(2):139-48. PubMed ID: 12616105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas.
    Torres LA; Coca MA; Batista JF; Casaco A; Lopez G; García I; Perera A; Peña Y; Hernández A; Sanchez Y; Romero S; Leyva R; Prats A; Fernandez R
    Nucl Med Commun; 2008 Jan; 29(1):66-75. PubMed ID: 18049099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients.
    Buchegger F; Bonvin F; Kosinski M; Schaffland AO; Prior J; Reubi JC; Bläuenstein P; Tourwé D; García Garayoa E; Bischof Delaloye A
    J Nucl Med; 2003 Oct; 44(10):1649-54. PubMed ID: 14530481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor imaging in patients with advanced tumors using a new (99m) Tc-radiolabeled vitamin B12 derivative.
    Sah BR; Schibli R; Waibel R; von Boehmer L; Bläuenstein P; Nexo E; Johayem A; Fischer E; Müller E; Soyka JD; Knuth AK; Haerle SK; Schubiger PA; Schaefer NG; Burger IA
    J Nucl Med; 2014 Jan; 55(1):43-9. PubMed ID: 24337606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
    Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA
    J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial peptide 99mTc-ubiquicidin 29-41 as human infection-imaging agent: clinical trial.
    Akhtar MS; Qaisar A; Irfanullah J; Iqbal J; Khan B; Jehangir M; Nadeem MA; Khan MA; Afzal MS; Ul-Haq I; Imran MB
    J Nucl Med; 2005 Apr; 46(4):567-73. PubMed ID: 15809477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of 99mTc-labeled interleukin-8 in experimental inflammation and infection.
    Rennen HJ; Boerman OC; Oyen WJ; Corstens FH
    J Nucl Med; 2003 Sep; 44(9):1502-9. PubMed ID: 12960199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma.
    Li S; Peck-Radosavljevic M; Kienast O; Preitfellner J; Havlik E; Schima W; Traub-Weidinger T; Graf S; Beheshti M; Schmid M; Angelberger P; Dudczak R
    Q J Nucl Med Mol Imaging; 2004 Sep; 48(3):198-206. PubMed ID: 15499293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
    Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 99mTc-exendin(9-39)/octreotide: biokinetics and radiation dosimetry in healthy individuals.
    Ocampo-García BE; Santos-Cuevas CL; Luna-Gutiérrez MA; Ignacio-Alvarez E; Pedraza-López M; Manzano-Mayoral C
    Nucl Med Commun; 2017 Nov; 38(11):912-918. PubMed ID: 28953210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
    Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
    Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
    J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation dosimetry of a 99mTc-labeled IgM murine antibody to CD15 antigens on human granulocytes.
    Mozley PD; Stubbs JB; Dresel SH; Barraclough ED; Smith T; Patel M; Finkelman C; Sparks RB; Thakur ML; Mathur A; Alavi A
    J Nucl Med; 1999 Apr; 40(4):625-30. PubMed ID: 10210221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study.
    Gabriel M; Decristoforo C; Wöll E; Eisterer W; Nock B; Maina T; Moncayo R; Virgolini I
    Cancer Biother Radiopharm; 2011 Oct; 26(5):557-63. PubMed ID: 21883013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in women.
    Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Pichardo-Romero PA
    Nucl Med Commun; 2008 Aug; 29(8):741-7. PubMed ID: 18753829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sentinel lymph node diagnosis in prostatic carcinoma: II. Biokinetics and dosimetry of 99mTc-Nanocolloid after intraprostatic injection].
    Wengenmair H; Kopp J; Vogt H; Wawroschek F; Gröber S; Dorn R; Heidenreich P
    Nuklearmedizin; 2002 Apr; 41(2):102-7. PubMed ID: 11989296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.